Related Experiment Videos
Biomarkers for melanoma.
Sima Torabian1, Mohammed Kashani-Sabet
1Auerback Melanoma Research Laboratory, Cutaneous Oncology Program, UCSF Comprehensive Cancer Center, and Department of Dermatology, University of California San Fransisco, California 94115, USA.
Current Opinion in Oncology
|February 24, 2005
Summary
Identifying effective melanoma biomarkers is crucial for predicting disease progression and guiding treatment. Advances in molecular markers improve detection and prognosis for melanoma patients, with future potential in gene expression profiling.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Melanoma is characterized by its unpredictable behavior, necessitating reliable biomarkers.
- Accurate identification of patients at risk for progression and those who will benefit from systemic therapy is critical.
Purpose of the Study:
- To review molecular prognostic markers in primary melanoma.
- To discuss markers for detecting metastatic melanoma.
- To explore markers predictive of response to systemic therapy.
Main Methods:
- Review of recent advances in melanoma biomarker research.
- Analysis of RT-PCR assays utilizing paraffin-embedded tissue and multiple markers.
- Investigation of lymphangiogenesis and NF-kappaB signaling pathway markers.
- Evaluation of loss of heterozygosity and serum S100B protein.
Main Results:
- Improved RT-PCR assays enhance melanoma cell detection in lymph nodes and blood.
- Lymphangiogenesis identified as a key mechanism in melanoma progression.
- NF-kappaB pathway markers implicated in melanoma-vasculature interactions.
- Serum S100B protein demonstrates superiority over lactate dehydrogenase in predicting prognosis and treatment response in advanced melanoma.
Conclusions:
- Significant progress has been made in developing melanoma biomarkers.
- Gene expression profiling and proteomics are expected to yield more effective biomarkers for melanocytic neoplasms.